Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer.

Cancer research communications - 1 Apr 2026

Jeon Yo Han, Lim Ahjin, Choi Myung Kyung, Choi Hee Seong, Lee Yurimi, Song Hyunju, Cho Hyun-Soo, Cho Jeonghee, Choi Yoon-La

Abstract excerpt

Non-small cell lung cancer (NSCLC) with EGFR L833V/H835L in cis mutation remains poorly understood. We retrospectively reviewed the clinicopathologic features of NSCLC with either EGFR L833V or H835L mutation. The study population includes patients with NSCLC (n = 3,835) at Samsung Medical Center, Seoul, Korea. A total of eight patients with EGFR L833V/H835L in cis mutation were identified. Poorly differentiated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to NIH 3T3 Cells

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42018150
DOI: 10.1158/2767-9764.CRC-25-0831
PMCID: PMC13101886

Genes

EGFR
F3
IL3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer.PMID 42018150Read ↗

Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report.Semantic proximity Read ↗

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.Semantic proximity Read ↗

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature reviewSemantic proximity Read ↗

[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].Semantic proximity Read ↗

A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature reviewSemantic proximity Read ↗

EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.Semantic proximity Read ↗

Emerging paradigms in targeted treatments for Asian patients with NSCLC.Semantic proximity Read ↗

V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Semantic proximity Read ↗

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer.Semantic proximity Read ↗

Involvement of MicroRNA-1-FAM83A Axis Dysfunction in the Growth and Motility of Lung Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.